Type 1 Diabetes (IMAGE) La Jolla Institute for Immunology Caption A promising therapeutic candidate for type 1 diabetes combines anti-IL-21 antibody with the diabetes drug liraglutide. Credit La Jolla Institute for Immunology Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.